Premium
Liquid chromatographic assay for the non‐peptidic protease inhibitor tipranavir in plasma
Author(s) -
Sparidans Rolf W.,
Dost Frits,
Crommentuyn Kristel M. L.,
Huitema Alwin D. R.,
Schellens Jan H. M.,
Beijnen Jos H.
Publication year - 2006
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.667
Subject(s) - chemistry , chromatography , protease inhibitor (pharmacology) , plasma , virology , physics , quantum mechanics , biology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Tipranavir is the most recently introduced protease inhibitor for the suppression of the human immunodeficiency virus (HIV). A selective reversed‐phase liquid chromatographic assay, previously developed for atazanavir, has been extended and validated for tipranavir in plasma. Compounds were isolated from a 500 µL plasma sample using liquid–liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using reversed‐phase liquid chromatography and ultra violet detection at 280 nm. In the evaluated concentration range (0.2–50 µg/mL tipranavir), intra‐day precisions were ≤8% and inter‐day precisions were ≤10%. Accuracies between 95 and 108% were found. The clinical applicability of the assay was demonstrated in an HIV‐infected patient who ingested 500 mg tipranavir bid in combination with 100 mg ritonavir. Copyright © 2006 John Wiley & Sons, Ltd.